Early development of anti-PD-1/PD-L1 in advanced NSCLC demonstrated long lasting responses translating into long term survival for approximately 15% of patients. Five phase III studies including mainly unselected patients compared anti-PD-1/PD-L1 as single agent with docetaxel in 2nd line setting. Four studies showed a significant OS benefit, doubling 2-year survival rates and a better tolerance profile with around 10% grade 3-4 immune-related adverse events. The lack of PFS improvement and an increase in the early death rates in one trial underscored the need for a better patients selection. PD-L1 expression appears as an enrichment factor correlated with the probability of response and the magnitude of OS benefit. The development of pembrolizumab has established more than 50% of tumor cells expressing PD-L1 as the best cutoff for a high probability of response. Other predictive biomarkers are under investigation, notably the tumor mutational burden. In 1st line setting, the Keynote 024 trial compared pembrolizumab to platinum-based doublet in tumors with high PD-L1 expression and demonstrated a large OS benefit with 30 months median survival compared to 14.2 months in the control arm despite a cross over in 62% of patients, establishing pembrolizumab as the new standard of care for these patients. The 2nd lead combined anti-CTLA4 and anti-PD1/PD-L1 with an announcement of a significant PFS benefit for ipilimumab-nivolumab combination compared to 1st line chemotherapy in case of TMB > 10 mutations/Mb. The 3rd lead in 1st line setting assessed in unselected patients combinations of cytotoxic chemotherapy and anti-PD-1/PD-L1. The addition of atezolizumab to carboplatin-paclitaxel-bevacizumab provided a significant PFS improvement while the combination of pembrolizumab to a platinum-pemetrexed regimen improved both PFS and OS. These new combinations will change the NSCLC treatment algorithm, underscoring the need of predictive biomarkers for patients selection.
CITATION STYLE
Perol, M. (2018). Key roles of immune-check inhibitors for first- and second line treatment for advanced NSCLC. Annals of Oncology, 29, vii15. https://doi.org/10.1093/annonc/mdy354
Mendeley helps you to discover research relevant for your work.